替比夫定联合水飞蓟宾治疗乙型病毒性肝炎患者的临床研究

目的观察替比夫定联合水飞蓟宾对乙型病毒性肝炎(乙肝)患者的谷丙转氨酶(GPT)、谷草转氨酶(GOT)、乙肝病毒脱氧核糖核酸(HBV DNA)影响。方法将乙肝患者136例随机分为对照组68例和试验组68例。对照组给予替比夫定,每次600 mg,每天1次;试验组在对照组的基础上给予水飞蓟宾,根据患者状况,每次70~140 mg,每天3次。2组均持续治疗24周。比较患者治疗前后GPT、GOT、HBV DNA水平指标变化。结果治疗后,对照组及试验组GPT分别为(139.08±63.28)和(78.58±39.99)U·L^-1,GOT分别为(173.22±70.18)和(86.58±48.84)U·L^-1;治疗后第24周HBV DNA水平分别为(2.69±0.41)和(2.01±0.39)log 10 U·mL^-1,差异均有统计学意义(均P<0.05)。2组患者均未出现明显的头痛、腹痛、恶心、腹泻和消化不良等症状。结论替比夫定合并水飞蓟宾治疗乙肝患者安全可靠,且对患者肝损伤相关GPT、GOT、HBV DNA指标有着显著的改善效果。

Clinical trial of telbivudine combined with silibinin in the treatment of patients with hepatitis B virus

Objective To observe the effect of telbivudine combined with silibinin on glutamic-pyruvic transaminase(GPT), glutamic-oxaloacetic transaminase(GOT), hepatitis B virus(HBV DNA)in the treatment of patients with hepatitis B virus. Methods A total of 136 patients with hepatitis B virus were randomly divided into control group(68 cases) and treatment group(68 cases). Control group was treated with telbivudine, 600 mg each time, once a day;treatment group was given silibinin, 70 to 140 mg each time according to the patient’s condition, three times a day, on the basis of control group. All patients were treated for 24 weeks. The changes of GPT, GOT and HBV DNA levels before and after treatment in two groups were compared. Results After treatment, the GPT in control group and treatment group were(139.08±63.28) and(78.58±39.99) U·L^-1, the GOT were(173.22±70.18) and(86.58±48.84) U·L^-1;the HBV DNA levels in twenty-fourth in the two groups were(2.69±0.41) and(2.01±0.39) log10 U·mL^-1, all with signi-ficant difference(all P<0.05). No significant headache, abdominal pain, nausea, diarrhea, or indigestion were observed in two groups. Conclusion The combination of telbivudine and silibinin in the treatment of patients with hepatitis B virus is safe and feasible, and has significant improvement effects on liver injury-related GPT,GOT,and HBV DNA.